Greg Winter

Professor & Nobel Laureate
University Cambridge

Sir Greg Winter studied Natural Sciences at University of Cambridge. He completed his PhD at the LMB, working on amino acid sequence of tryptophanyl tRNA synthetase from the bacterium Bacillus stearothermophilus. His research career has been mostly based at the LMB and the MRC Centre for Protein Engineering (CPE).

He became Programme Leader in 1981, was Joint Head of the PNAC Division from 1994-2006, Deputy Director of the LMB from 2006-2011 and acting Director 2007-2008. He was Deputy Director of CPE from 1990 until its 2010 closure. His main research focus is genetic and protein engineering. In his early research Greg was interested in the idea that all antibodies have the same basic structure, with only small changes making them specific for one target. He pioneered techniques in humanised and human therapeutic antibodies, which led to antibody therapies for cancer and diseases such as rheumatoid arthritis and multiple sclerosis.

He has established hugely successful spin out companies including: Cambridge Antibody Technology (acquired by AstraZeneca), Domantis (acquired by GlaxoSmithKline) and Bicycle Therapeutics. He is a Fellow of Trinity College, Cambridge and was Master of Trinity 2012-2019. He was elected member of the European Molecular Biology Organisation in 1987, Fellow of the Royal Society in 1990 and Fellow of the Academy of Medical Sciences in 2006; was a Fellow or Honorary Fellow of many other professional organisations. He has been awarded numerous prizes and medals, including the 2018 Nobel Prize for Chemistry. He received a Knighthood for services to Molecular Biology in 2004.